Nanosphere — IPO Roadshow (December 2015)
24 slides from Nanosphere's IPO roadshow presentation, Dec 10, 2015
Slide 1: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS historical This presentation facts, included contains in forward-looking this presentation statements regarding our about strategy, us and future our industry operations, that involve future financial substantial position, risks and future uncertainties. net sales, project
Slide 2: Our Mission
OUR MISSION Enhance Medicine Through Targeted & Flexible Diagnostics Improve Patient Care o Save lives o Decrease morbidity o Reduce spread of antibiotic resistance Lower Costs to the Healthcare System o Shorter length of stay o Antibiotic savings o Demonstrated economic outcomes o Minimize unnecess
Slide 3: Why We Believe We Will Succeed
WHY WE BELIEVE WE WILL SUCCEED Installed Base o Over 300 U.S. microbiology customer placements and growing o Leverage through expanding menu Reliable and Versatile Technology o Clinical evidence validates exceptional performance o Detection of organism and drug resistance, proteins o Flexible report
Slide 4: Two Main Drivers of MDx Markets
TWO MAIN DRIVERS OF MDX MARKETS Need for more timely Need to address Need and cost-effective costly and complex results disease states High Count Sample-To- Product Feature Multi- Result Plexing Conversion of traditional culture-based methods to molecular will be driven by the need for rapid and cli
Slide 5: Progress and Future Driven by Proprietary Markets
PROGRESS AND FUTURE DRIVEN BY PROPRIETARY MARKETS Nanosphere’s Proprietary Markets (2011-2015) RP Flex $1B (~$400M) Over $1B of Proprietary Markets RP Flex Size in 2015 $750M Market Enteric (~$400M) Enteric (~$400M) Proprietary $500M Enteric BSI (~$300M) BSI (~$300M) BSI (~$300M) BSI (~$300M) $250M
Slide 6: Expanding Menu & Customer Base
EXPANDING MENU & CUSTOMER BASE Regulatory Status Est. Ann. Microbiology Menu FDA CE IVD Rev/Cust Market Dynamics Respiratory Panel $70 K Flex™ Capability BSI—Gram Positive $50 K Proprietary—Accuracy C. difficile $30 K Competitive—Price Competitive BSI—Gram Negative $30 K Proprietary—Accuracy Enteric
Slide 7: Sepsis: Acute and Growing Problem
SEPSIS: ACUTE AND GROWING PROBLEM Delayed Diagnosis & Cost Intervention Mortality BSI is the most costly As each hour passes reason for U.S. 16.5% without targeted inpatient (Eight times higher intervention, hospitalization than any other BSI causes an 8% ($15.4B annually) diagnosis) increase in mor
Slide 8: Microbiology Test Requirements
MICROBIOLOGY TEST REQUIREMENTS Targeted AND Multiplexed (Flexible) o Multiple infectious target identification & resistance o Clinically actionable result Accurate o >95% sensitivity o >95% specificity Fast o Rapid turnaround time Easy to Use o Sample-to-result On Demand o Random access Moderate Com
Slide 9: Verigene Impact
VERIGENE® IMPACT NANOSPHERE COMPANY OVERVIEW Traditional Blood Culture Workflow Blood Culture Culture Samples Plated for Sub-Culture Resistance Testing and Gram Stain Results Hours 12 15 24 48 Verigene Workflow The Verigene Workflow provides identification and resistance information 2-2.5 hours afte
Slide 10: Verigene Changes the Game
VERIGENE CHANGES THE GAME Saves Last Line Saves Money Therapies Saves Lives Recent study by UF Shands New Hanover Regional Medical Center: 80% reduction in 21.7 day reduction in 60 hour reduction to I.C.U. mortality Length of stay/patient discontinuation of from 47.8% unnecessary therapy to 9.5% $61
Slide 11: Verigene Impact in Community Hospitals
VERIGENE IMPACT IN COMMUNITY HOSPITALS Scripps Memorial Hospital1 25.3 hour reduction in time to optimal therapy 5.1 day length of stay reduction $10,547 reduction in hospital costs per patient Blount Memorial Hospital2 21.0 hour reduction in time to optimal therapy 3.5-day ICU length of stay reduct
Slide 12: Competitive Advantages
COMPETITIVE ADVANTAGES NANOSPHERE COMPANY OVERVIEW Rapid Blood Culture Testing Benefits Versus BioFire Nanosphere direct detection (no PCR) provides for ?Reduce Mortality: Each hour that appropriate accuracy in both sensitivity and specificity required for antimicrobial treatment is delayed, a sepsi
Slide 13: Superbugs Are Making Headlines
SUPERBUGS ARE MAKING HEADLINES
Slide 14: Emergence of Carbapenem-Resistant Enterobacteriaceae (CRE)
EMERGENCE OF CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) Source: M. McKenna. Nature. Vol 499. 25 July 2013.
Slide 15: CDC Landmark Recommendations
CDC LANDMARK RECOMMENDATIONS Burden and Threat Posed by Antibiotic-Resistant Infections o Drug resistant infections are a threat to human and economic health o Overuse of antibiotics is the single most important factor o > 10 million deaths per year by 2050 due to antimicrobial resistance1 o Urgent
Slide 16: Solving the Enteric Problem
SOLVING THE ENTERIC PROBLEM Large Market Opportunity o 3.7 million U.S. emergency department visits in 2010 for unknown gastrointestinal symptoms of bacterial or viral pathogens o 1.3 million resulted in hospitalizations Costly to the Healthcare System o U.S. patients suffering from gastrointestinal
Slide 17: Verigene Flex System
VERIGENE FLEX SYSTEM One Instrument One Consumable Room Temperature Optimal Footprint Reduced Assay Time Easy Workflow
Slide 18: Verigene Flex System
VERIGENE FLEX SYSTEM Compact o Each instrument is equivalent to 1 Reader and 6 SPs Hands-off Sample-to-Result o All processing and analysis occurs in the same box Single Consumable Design
Slide 19: Verigene Flex System
VERIGENE FLEX SYSTEM Current Verigene System Next Generation Verigene System Competitive Best-in-Class High multiplexed ? One step sample-to-result ? Accurate ? Flexibility / Cost per test ? Flexible ? Consolidates consumables ? Easy to use ? Room temperature stability ? On demand ? Optimal footprin
Slide 20: Global Commercial Strategy
GLOBAL COMMERCIAL STRATEGY U.S. Direct Sales Force o Productivity now Driving Execution Placement penetration Contract time to live implementation Accelerate contract conversion Purchase/Rental Drive menu through current customer base o Gram Negative o Enteric o Respiratory Flex Europe Distribution
Slide 21: Technology Targets
Technology Targets Multiple Applications Diag es DNA 1) Multiplexed nucleic acid panels Gold nanoparticle • Infectious diseases RNA Human genetics, personalized medicine Security/defense Proteins 2) High sensitivity and/or multiplexed protein • cTnI, PSA Rheumatoid arthritis Significant Potential •
Slide 22: Low Risk Margin Expansion
LOW RISK MARGIN EXPANSION 85% 75% 65% % 2015 margin drivers: Materials (mostly Profit reagents) Gross 55% Consumable mix 45% 2014 margin drivers: 35% Substrate & cavitation Labor reduction 25% 2013 2014 2015 2016 2017 Annual Test Sales Volume Consumables GP% System Sales GP% Combined GP%
Slide 23: Evidence of Our Belief
EVIDENCE OF OUR BELIEF Leverage in Customer Base Expanding Menu Best-in-Class Performance Novel Flex™ tests designed to better compliment how healthcare is practiced Differentiating Value in Protein De-Risked for Technology/Regulatory/Reimbursement Straightforward Cost Reduction Leverage Focus on Ex
Slide 24: Nanosphere Company Overview, Evidence of Our Belief
NANOSPHERE COMPANY OVERVIEW, EVIDENCE OF OUR BELIEF ¢ Leverage in Customer Base * Expanding Menu * Best-in-Class Performance * Novel Flex™ tests designed to better compliment how healthcare is practiced ¢ Differentiating Value in Protein * De-Risked for Technology/Regulatory/Reimbursement * Straight